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Abstract
Aims: The overactive bladder quality of life short‐form questionnaire (OAB‐q
SF) evaluates both symptom bother and health‐related quality of life in patients
with OAB, a highly prevalent disease. The objective of this study was to
translate and validate a Dutch version of the OAB‐q SF.
Methods: The translation into Dutch and validation process of the OAB‐q SF
was performed according to standardized guidelines. Patients with OAB who
visited the department of Urology outpatient clinic completed the question-
naires OAB‐q SF, European Quality of life 5‐Dimension 5‐Level questionnaire
(EQ‐5D‐5L), Urogenital Distress Inventory 6 (UDI‐6), and the International
Consultation on Incontinence Questionnaire Overactive Bladder (ICIQ‐OAB) at
baseline (test) and 2 weeks later (retest). A reference group from the department
of Allergology outpatient clinic completed the same questionnaires once. The
evaluated measurement properties included content validity, internal consis-
tency, reproducibility, criterion validity, and construct validity.
Results: Fifty‐two patients were included in the study group and 51 references
were included. The content validity was adequate and the internal consistency
was excellent (Cronbach’s α> 0.80). The reproducibility was good with
intraclass correlation coefficients higher than 0.70. Patient’s OAB‐q SF scores
were moderately to strongly correlated with the UDI‐6, ICIQ‐OAB, and the
EQ‐5D‐5L confirming the criterion validity. A good construct validity was
demonstrated with significant higher scores of the OAB‐q SF score in patients
compared to references.
Conclusions: The Dutch OAB‐q SF is a reliable and valid measure to evaluate
symptom bother and health‐related quality of life in patients with OAB.
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1 | INTRODUCTION
Overactive bladder (OAB) is defined as urgency, with or
without urgency urinary incontinence, usually associated
with frequency and nocturia. The prevalence of this
condition is described to be between 13% to 16%
worldwide, and is expected to increase as a result of the
aging of the population. It has been shown to have a great
negative impact on an individual’s health‐related quality
of life (HRQOL). All this causes a high burden on
society.1-3
OAB is a symptom‐based condition, with low‐positive
and negative predictive values for urodynamic investiga-
tions.4,5 The best method available to diagnose disease,
quantify disease severity, and evaluate treatment effects
is therefore the use of patient‐reported outcome’s (PROs),
usually in the form of a questionnaire. Since the
introduction of PROs, many different questionnaires
have been developed. To compare the burden of OAB
in patients and define guidelines for treatment, con-
sensus is necessary on the specific questionnaire to use.
The EAU (European Association of Urology) and the ICS
(International Continence Society) guidelines do not
recommend specific questionnaires to use for OAB, but
both professional organizations mention that it is
important to use questionnaires validated in the language
of use.6,7 The International Consortium for Health
Outcome measurements (ICHOM) aims to improve
value‐based healthcare by defining global standard sets
of outcome measures for different conditions. A core set
of outcome measures for OAB which includes the OAB‐q
SF questionnaire, was developed in 2017.8
The OAB‐q Short Form (SF) is a worldwide used
questionnaire for health‐related quality of life in patients
with OAB. OAB‐q SF is the shorter version of the 33‐item
“OAB‐q” questionnaire. The OAB‐q SF includes 19 items;
a six‐item symptom bother scale and a 13‐item health‐
related quality of life (HRQOL) scale.9,10
Before implementing the ICHOM set of outcome
measures for OAB in the Netherlands, the OAB‐q SF
questionnaire needs to be translated and validated in
Dutch. Therefore, the aim of this study is to translate and
validate the OAB‐q SF in the Dutch language.
2 | MATERIALS AND METHODS
2.1 | Study design
This is a single‐center, prospective cohort validation
study, for which approval was obtained by the Ethics
Review Board.
2.2 | Patient group
All patients seen at the Urology outpatient clinic in between
April 2018 and February 2019 diagnosed with OAB were
eligible for screening. OAB was defined as urinary urgency,
with or without urinary incontinence. Inclusion criteria were
age 18 years and above and being fluent and literate in the
Dutch language. Exclusion criteria consisted of urinary
diversions, a history of/or active malignant tumors of the
urinary tract, hematuria, bladder stones, neurogenic bladder,
dementia, mental retardation, and symptomatic urinary tract
infection. The treating physician explained the study to
patients eligible for inclusion and invited to participate. After
signing informed consent patients were asked to complete
the questionnaires during the inclusion visit (test) and 2
weeks later at home (retest). Characteristics of the included
patients were extracted from the medical records.
2.3 | Reference group
Patients who visited the department of Allergology
outpatient clinic between September 2019 and December
2019 were invited as reference group. Inclusion criteria
were age 18 years and above and being fluent and literate
in the Dutch language. Exclusion criteria consisted of a
urological medical history or current bladder problems,
dementia, and mental retardation. We considered these
patients as a proper control group as allergy pathology
has no relationship with bladder problems; those with
bladder problems were indeed not eligible for inclusion
in the reference group. Patients who met inclusion
criteria were informed by their treating physician and if
willing to participate, informed consent was signed and
one set of questionnaires was completed.
3 | QUESTIONNAIRES
The questionnaire set included four questionnaires: the
OAB‐q SF, the European Quality of life 5‐Dimension
5‐Level questionnaire (EQ‐5D‐5L), the Urogenital Dis-
tress Inventory 6 (UDI‐6), and the International Con-
sultation on Incontinence Questionnaire Overactive
Bladder (ICIQ‐OAB).
• The OAB‐q SF is a 19‐item, self‐administered disease
specific instrument derived from the OAB‐q.9,10 The
OAB‐q SF contains two main subscales: Symptom
bother (six items) and Health‐Related Quality of Life
(HRQOL, 13 items). Each item is rated on a six‐point
Likert scale, for the symptom bother scale ranging from
0 (not at all) to 6 (a very great deal) and for the HRQOL
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scale from 0 (none of the time) to 6 (all of the time). The
two subscales are separately summed and, on the
guidance of the scoring manual,9 transformed into
scores ranging from 0 to 100. A higher score on the
symptom bother scale indicates a greater symptom
severity and a higher score on the HRQOL scale
indicates a better HRQOL, so they are inversely related
to each other. These two scores, are always be
mentioned separately, since the OAB‐q SF has no total
score.
• The EQ‐5D‐5L questionnaire (European Quality of life
5‐Dimension 5‐Level questionnaire) developed by the
EuroQol group, is one of the most used PRO instru-
ments for the measurement of HRQOL.11 It consists of
five questions addressing mobility, self‐care, activities,
pain/discomfort, and anxiety/depression, the answers
are transformed to an index value ranging from 0
(inability) to 1 (no problems) by using the accessory
index value calculator. In addition, the health state is
self‐reported by completing a visual analog scale (VAS)
ranging from 0 “the worst health you can imagine” to
100 “the best health you can imagine.”
• The UDI‐6 is a six‐item symptom inventory, specific to
symptoms associated with lower urinary tract dysfunc-
tion. It combines information on irritative, stress and
obstructive/discomfort symptoms of the lower urinary
tract.12 This questionnaire has been translated and
validated in Dutch and the mean score of the six items
is converted to a 0 to 100 scale on the guidance of the
scoring manual.13
• The ICIQ‐OAB questionnaire indicates the symptom
bother of frequency, nocturia, urge, and incontinence
in four questions. The impact on quality of life of these
four problems is self‐reported by completing four
bother scales from 0 to 10. According to the design of
the questionnaire the results of the ICIQ‐OAB ques-
tions are summed creating a score; ICIQ‐OAB Q
(questions). Furthermore, in the present study the
bother scales are summed; ICIQ‐OAB BS (bother
scales), creating a value ranging from 0 to 40 indicating
the HRQOL. The design of the questionnaire does not
indicate how to calculate the total score of the bother
scales.
4 | CROSS ‐CULTURAL
ADAPTION
The cross‐cultural adaption of the original English OAB‐q
SF into the Dutch language was done according to the
standardized guidelines for linguistic validation.14 The
forward translation of the English OAB‐q SF into
the Dutch OAB‐q SF was performed by three professional
native Dutch‐speaking translators separately. During a
consensus meeting discrepancies between the three transla-
tions were discussed with the translators, two urologists (BB
and JS) and the primary investigator (IG). The final version
(see the Supporting Information material) was backward‐
translated by a native English‐speaking translator. To
confirm the content validity of the Dutch version, the
questionnaire was evaluated face‐to‐face with five patients
visiting the urology outpatient clinic.
5 | MEASUREMENT PROPERTIES
5.1 | Content validity
The content validity was assessed during the linguistic
validation by patient and researchers (IG, BB, and JS).
Researchers subjectively evaluated the correspondence
between the clinical symptoms of OAB and the questions.
Patients reported on the formulation of the questions and
clarity of the questions during the face‐to‐face evaluation.
5.2 | Internal consistency
By assessing the correlation between different items
within the questionnaire, the internal consistency is
examined, demonstrating whether the items measure the
same underlying construct. The Cronbach’s α was
calculated for the two subscales of the OAB‐q SF. A
Cronbach’s α between 0.70 and 0.95 was considered to
reflect adequate internal consistency.15
5.3 | Reproducibility
The reproducibility is the degree to which repeated
measurements in the test‐retest period provide similar
answers. When testing the reproducibility, a distinction
between the reliability and agreement is made.15,16
Reliability is determined by the degree to which patients
can be differentiated from each other, despite the
measurement error. This was expressed by the intraclass
correlation coefficient (ICC) for agreement, scores over
0.70 are acceptable. Furthermore, the agreement indi-
cates the measurement error which is the similarity in
scores rated on separate occasions. The limits of
agreement (LOA) were expressed as the mean change
in scores of repeated measurements of 1.96 × standard
deviation of the changes.16,17
5.4 | Criterion validity
The criterion validity, that is, the extent to which the
OAB‐q SF questionnaire scores relate to a gold standard,
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is determined with the Pearson’s correlation coefficient
(range, −1 to 1) in case of a linear association and when a
linear association is not seen, the Spearman correlation
coefficient. For OAB, a gold standard does not exist, and
instead the UDI‐6 and the ICIQ‐OAB (Q and BS) served
as such.
5.5 | Construct validity
Predefined hypotheses about the relation of the OAB‐q
SF to other instruments were tested. The construct
validity is considered adequate when at least 75% of the
results of predefined hypotheses are in accordance.15 The
following hypotheses were formulated:
1. The reference group will have lower OAB‐q SF
symptom bother scores and higher OAB‐q SF HRQOL
scores than the patient group.
2. Patients with a higher UDI‐6 score will have a higher
OAB‐q SF symptom bother score.
3. Patients with a higher ICIQ‐OAB Q (questions) score
will have a higher OAB‐q SF symptom bother score.
4. Patients with a higher ICIQ‐OAB BS (bother scale)
score will have a lower OAB‐q SF HRQOL score.
5. Patients with a lower EQ‐5D‐5L index value and
patients with a lower EQ‐5D‐5L VAS will have a
lower score on the OAB‐q SF HRQOL.
5.6 | Floor and ceiling effects
Floor and ceiling effects were considered if more than
15% of the respondents would achieve the lowest‐ or
highest‐possible score.15 The floor and ceiling effects
were calculated for symptom bother and HRQOL scores
at baseline in the patient and in the reference group.
6 | STATISTICAL METHOD
A sample size of at least 50 participants was considered
adequate for validation of questionnaires,15 thus we
aimed to include a total of 100 patients, 50 in the patient
group and 50 in the reference group. Continuous data are
presented as mean, standard deviation (SD). The Student
t test and the χ 2 test for continuous and categorical
variables, respectively, were used evaluating differences
between patient and reference group. Statistical analyses
were performed using SPSS version 24.0 (IBM Corp,
Armonk, NY). Statistical significance was defined as
P< .05.
7 | RESULTS
In total, 103 participants were included in the study. In
the patient group, 56 patients signed an informed
consent, of whom 52 patients completed the ques-
tionnaires at both time points. Four patients did not
return the second questionnaire and were therefore
excluded from the analyses. The reference group
consisted of 51 participants who completed the ques-
tionnaires at one time point. Table 1 displays the
patient characteristics and the baseline scores of the
four questionnaires.
7.1 | Content validity
Content validity was confirmed during the face‐to‐face
evaluation of the questionnaire. Question 8 of the OAB‐q SF
HRQOL subscale was discussed, but did not lead to changes






(N= 52) P value
Age, y 41 (±15) 64 (±13) .02*
Sex, n (%) .24**
Male 14 (28) 20 (39)





12.4 ± 15.4 63.8 ± 21.6 <.001*
OAB‐q SF
HRQOL




0.881 ± 0.156 0.738 ± 0.212 .086*
EQ‐5D‐5L
VAS
76.1 ± 14.3 71.7 ± 17.3 .043*
UDI‐6 8.9 ± 9.1 57.7 ± 20.7 <.001*
ICIQ‐OAB
Q (questions)




3.8 ± 6.3 29.4 ± 8.1 .037*
Abbreviations: EQ‐5D‐5L, European Quality of life 5‐Dimension 5‐Level
questionnaire; HRQOL, health‐related quality of life; ICIQ‐OAB, Interna-
tional Consultation on Incontinence Questionnaire Overactive Bladder;
OAB‐q SF, overactive bladder quality of life short‐form questionnaire; UDI‐
6, Urogenital Distress Inventory 6; VAS, visual analog scale.
Significance of the values set in italics is (< 0.05).
*Student t test.
**χ2 test.
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in the questionnaire. Furthermore, the face‐to‐face evalua-
tion demonstrated that patients found the questionnaire
understandable, easy to complete and clear.
7.2 | Internal consistency
The internal consistency of the questionnaire was tested
good for both subscales. Cronbach’s α’s between 0.70 and
0.95 reflect adequate internal consistency. In the patient
group the OAB‐q SF symptom bother subscale the
Cronbach’s α scores were 0.84 and 0.87 for test and
retest, respectively. For the OAB‐q SF HRQOL subscale
the Cronbach’s α were 0.88 and 0.91 for test and retest,
respectively.
7.3 | Reproducibility
In the patient group, the second questionnaire was
returned after a mean of 15.8 days (SD ± 11). An
adequate reliability was confirmed with ICCs higher
than 0.70 for the two subscales of the OAB‐q SF. Table 2
lists the ICCs for agreement and LOA ranges for the two
subscales of the OAB‐q SF.
7.4 | Criterion validity
Using the Pearson correlation coefficient a moderate to very
strong correlation was detected between the OAB‐q SF
symptom bother and the UDI‐6 and the ICIQ‐Q. The
criterion validity of the OAB‐q SF HRQOL was evaluated by
calculating the correlation with the IQIQ‐BS and the EQ‐
5D‐5L index values and VAS. Calculating the correlation
with the EQ‐5D‐5L index values, the spearman correlation
coefficient was used since no linear relationship was found
between the OAB‐q SF HRQOL and the EQ‐5D‐5L index
value. Correlations demonstrated a weak to strong correla-
tion (See Table 3 for ρ and P values).
7.5 | Construct validity
All predefined hypotheses were confirmed:
1. The reference group did have lower OAB‐q SF
symptom bother scores and higher OAB‐q SF HRQOL
scores compared to the patient group (Table 1).
2. Patients with a higher UDI‐6 score had a higher OAB‐
q SF symptom bother score (Table 3).
3. Patients with a higher ICIQ‐OAB Q (questions) score
had a higher OAB‐q SF symptom bother score
4. Patients with a higher ICIQ‐OAB BS (bother scale)
score had a lower OAB‐q SF HRQOL score (Table 3).
5. Patients with a lower EQ‐5D‐5L index value and a
lower EQ‐5D‐5L VAS had a lower score on the OAB‐q
SF HRQOL (Table 3).
7.6 | Floor and ceiling effects
In the patient group, no floor or ceiling effects were seen
for the two subscales (Table 4). In the reference group,
floor effects were seen for the symptom bother subscale;
17.6% scored the lowest possible score of 0. Moreover, in
the HRQOL subscale, a ceiling effect was seen, in that,
29.4% of patients scored the highest‐possible score.
8 | DISCUSSION
The primary aim of this study was to translate and
validate the OAB‐q SF in the Dutch language. The results
of this study showed that this Dutch version is valid,
reliable and consistent. This enables the use of the OAB‐q
SF in daily practice in the Netherlands. A valid tool to
measure both symptom bother and health‐related quality
of life in patients with OAB in an easy and fast way.
The content validity of the questionnaire was con-
firmed during the face‐to‐face evaluation. Question 8 of
the OAB‐q SF HRCOL subscale was discussed. One
patient commented on question 8 in the health‐related
quality of life subscale: “During the past 4 weeks, how
often have your bladder symptoms caused you to have
problems with your partner or spouse?” The issue was
that response option “not applicable” was lacking for
those who had no partner. Because adding this response
option would complicate the scoring manual, we
discussed this problem with the designers of the original
questionnaire.9 In the cohort of Coyne et al,9 patients
either leaved the question blank, and it was recorded as
missing, or patients answer was “None of the time” given
that when it is not applicable, it really is none of the time.
TABLE 2 The reproducibility is presented in term of the intraclass correlation coefficient (ICC) and the limits of agreement (LOA)
Change (mean± SD) ICC (95% CI) LOAa
OAB‐q SF symptom bother −4.23 ± 13.89 0.79 (0.66‐0.88) −31.45‐22.99
OAB‐q SF HRQOL 2.37 ± 10.83 0.85 (0.76‐0.91) −18.84‐23.58
Abbreviations: CI, confidence interval; HRQOL, health‐related quality of life; OAB‐q SF, overactive bladder quality of life short‐form questionnaire.
aCalculated as: y=mean(change) ± 1.96 × standard deviation (change).
GROENENDIJK ET AL. | 1779
Therefore the Dutch version did not insert “not applic-
able” as answer option, and no changes were made as a
result of this discussion.9 Moreover, according to the
scoring manual of the OAB‐q SF, the total score can be
adapted to up to 50% of missing items, still creating a
score ranging from 0 to 100.
The significantly different scores in the patient
group (higher in symptom bother and lower in
HRQOL) compared to the reference group, indicated
a good discriminative ability and possible diagnostic
value of the OAB‐q SF. Comparable to the Cronbach’s
α’s of the original OAB‐q SF (0.82 and 0.91) and the
Spanish validation (0.81 and 0.92),9,18 the Cronbach’s
α’s of the Dutch OAB‐q SF were good (0.83 to 0.89),
and demonstrated an excellent internal consistency.
Using the change in scores between the test‐retest, the
agreement and the limits of agreement were calcu-
lated, demonstrating an adequate reliability and
reproducibility. These results are in accordance with
the original OAB‐q SF study,9 and the Spanish
validation study.18
Concerning the criterion validity, the present study
used the UDI‐6, the ICIQ‐OAB, and the EQ‐5D‐5L to
correlate with the OAB‐q SF because of the absence of a
gold standard. As expected, the symptom bother subscale
showed a strong correlation with the UDI‐6 and the
ICIQ‐questionnaires for both test and retest. Moreover,
the OAB‐q SF HRQOL subscale showed a strong
correlation with the ICIQ‐bother scales, but the correla-
tions with the EQ‐5D‐5L index value and EQ‐VAS were
moderate. The ICIQ‐OAB bother scales are focused on
OAB symptoms and the EQ‐5D‐5L is more in general,
which might be a possible explanation for the moderate
compared to strong correlation. The Spanish validation
study also used the EQ‐5D and ‐VAS and showed
comparable, moderate correlations.18 All predefined
hypotheses in the present study were confirmed demon-
strating that patients and references are well distinguish-
able, and therewith showing a good construct validity.
In the patient group, no floor and ceiling effects were
detected, which implies that although many patients had
severe OAB, the questionnaire is still discriminative
enough to detect worsening or improvement of symptom
bother or in HRQOL. In the reference group, as expected,
a floor effect was found in the symptom bother scale
(17.5%), indicating that in the reference group patients
had no bother due to bladder problems. Moreover, a
ceiling effect was seen in the HRQOL scale (29.4%),
indicating that in the reference group, bladder problems
were not severe enough or not present to create a
decrease in HRQOL.
The strength of the current study is the use of
standardized measurement properties as described by
Terwee et al15 to evaluate the reliability and validity of
the OAB‐q SF. The current study did not determine the
responsiveness and interpretability due to short follow‐
up, and a lack of therapy changes over time in the study
group. This is a limitation of the study, however previous
literature on the English OAB‐q SF demonstrates a good
responsiveness and interpretability.9 There was a differ-
ence in the mean age between the patient and the
reference group. The reference group is only used for one
TABLE 3 Criterion validity measured using the Pearson correlation coefficient
UDI‐6 ICIQ‐Q ICIQ‐BS EQ‐5D‐5L index value EQ‐5D‐5L VAS
Test, ρ (P value)
OAB‐q SF symptom bother 0.56 (<.001) 0.84 (<.001) ⋯ ⋯ ⋯
OAB‐q SF HRQOL ⋯ ⋯ −0.67 (<.001) 0.46(<.001)a 0.49 (.001)
Retest, ρ (P value)
OAB‐q SF symptom bother 0.72 (<.001) 0.83 (<.001) ⋯ ⋯ ⋯
OAB‐q SF HRQOL ⋯ ⋯ −0.70(<.001) 0.43 (.002)a 0.33 (.016)
Abbreviations: EQ‐5D‐5L, European Quality of life 5‐Dimension 5‐Level questionnaire; HRQOL, health‐related quality of life; ICIQ‐OAB, International
Consultation on Incontinence Questionnaire Overactive Bladder; OAB‐q SF, overactive bladder quality of life short‐form questionnaire; UDI‐6, Urogenital
Distress Inventory 6; VAS, visual analog scale.
aSpearman’s correlation coefficient because of nonparametric correlation.
TABLE 4 Floor and ceiling effects at baseline
References












9 (17.6) 1 (2) 0 (0) 4 (7.7)
OAB‐q SF
HRQOL
0 (0) 15 (29.4) 0 (0) 0 (0)
Abbreviations: HRQOL, health‐related quality of life; OAB‐q SF, overactive
bladder quality of life short‐form questionnaire.
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of the four hypotheses of the construct validity. All
the other measurement properties are calculated without
the use of the reference group, so without influence of
this age difference. Another limitation of the study is the
absence of a gold standard to assess the criterion validity.
On the other hand, the absence of a gold standard in this
highly prevalent disease demonstrates the need for a
good PRO in OAB. The choice to implement the OAB‐q
SF in the ICHOM OAB‐set suggests that this question-
naire might be a valid PRO for OAB symptoms.
9 | CONCLUSION
In conclusion, this Dutch version of the OAB‐q SF
showed a good validity and reliability according to well‐
established guidelines on measurement properties. The
OAB‐q SF is a suitable instrument for assessing both
symptom bother and HRQOL in patients suffering from
OAB. We recommend the use of this measurement tool
in both research and clinical practice.
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